Data from Phase 2b of Opthea Limited wet AMD trial published

Author(s):

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.”

(Image credit: AdoeStock/Best)

Data from Opthea Limited’s sozinibercept Phase 2b data was published in the peer-reviewed journal, Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. The data was included in the paper – titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type” – which found pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naïve patients with wet AMD.

The results are based on choroidal neovascularization (CNV) type lesions, including occult, minimally classic, and predominantly classic, and the presence and absence of retinal angiomatous proliferation (RAP) on visual acuity and anatomical outcomes.

Phase 2b showed sozinibercept combination therapy had a statistically significant additional 5.7 letter mean gain in best correct visual acuity (BCVA) compared to ranibizumab alone in patients with occult and minimally classic lesions excluding RAP. A higher proportion of patients in this subgroup also had improved anatomy of better drying retina with reduced CNV area at week 24 compared to only using ranibizumab.

“Angiographic lesion characteristics being predictive of patient response are consistent with data reported in real-world trials and have informed the design of Opthea’ssozinibercept Phase 3 clinical program,” Frederic Guerard, PharmD, chief executive officer of Opthea, said. “In fact, the patient demographics and baseline characteristics from COAST and ShORe include a high proportion of enrolled patients with these best responding lesion types. We are looking forward to the anticipated topline data readouts for COAST in early Q2 CY 2025 and for ShORe in mid-CY 2025.”